SCHEDULE 13G/A: FMR LLC Reduces Stake in TYRA Biosciences Below 5% Threshold

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 3.2% in TYRA Biosciences Inc. as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, have filed an Amendment No. 5 to Schedule 13G regarding their beneficial ownership in TYRA Biosciences Inc.
• As of March 31, 2025, FMR LLC and Abigail P. Johnson collectively beneficially own 1,707,147.96 shares of TYRA Biosciences Inc. common stock.
• This aggregate amount represents 3.2% of the total outstanding common stock of TYRA Biosciences Inc.
• FMR LLC holds sole voting power over 1,706,765.00 shares and sole dispositive power over 1,707,147.96 shares.
• Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is also reported as having sole dispositive power over 1,707,147.96 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The filing indicates that one or more other persons have the right to receive dividends or proceeds from the sale of these securities, but no single other person's interest exceeds five percent of the total outstanding common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor below the 5% reporting threshold, which could imply a decrease in conviction or portfolio rebalancing.

Positives

• The continued, albeit reduced, investment by a major institutional investor like FMR LLC provides some level of ongoing confidence in TYRA Biosciences Inc.
• The filing demonstrates transparency regarding significant ownership changes by institutional investors.

Negatives

• FMR LLC's beneficial ownership has decreased to 3.2%, falling below the 5% threshold that typically triggers initial Schedule 13G filings, indicating a reduction in their stake or significant share dilution by TYRA Biosciences Inc.

Future Outlook

NA

Industry Context

FMR LLC is a prominent global asset management firm, and its investment in TYRA Biosciences Inc., a biotechnology company, reflects its portfolio allocation strategies within the life sciences sector. Changes in such a large investor's stake can be indicative of broader trends in institutional confidence in specific industries or companies.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional investor's stake may influence investor sentiment and potentially the stock price, signaling a change in institutional confidence.
• Company Management: May need to consider the implications of a major investor reducing their position, potentially prompting engagement with the investor or re-evaluation of company strategy.

Next Steps

• FMR LLC and Abigail P. Johnson will be required to file further amendments to Schedule 13G only if their beneficial ownership in TYRA Biosciences Inc. increases to 5% or more, or if there are other significant changes requiring disclosure under SEC rules.

Key Dates

Keywords

TYRA Biosciences, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, SEC Filing